• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Jan 9, 2023 | Press Releases

CINCINNATI, Jan. 09, 2023 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Jan 9, 2023 | Press Releases

CINCINNATI, Jan. 09, 2023 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Dec 12, 2022 | Press Releases

CINCINNATI, Dec. 12, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Dec 12, 2022 | Press Releases

CINCINNATI, Dec. 12, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

Dec 6, 2022 | Press Releases

CINCINNATI, Dec. 06, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

Dec 6, 2022 | Press Releases

CINCINNATI, Dec. 06, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
  • Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
  • Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
  • Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
  • Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2025 Onconetix